For the first time, MPSC will be attending the Gravens Conference from March 3rd-7th at the Sheraton Sand Key Resort in Clearwater Beach, Florida. MPSC is proud to attend this conference focused on the Physical and Developmental Environment of the High Risk Infant.
At the upcoming Cool Topics 2015 conference held at the Coronado Marriott Resort, MPSC will be exhibiting the HeRO range of products with the HeRO duet on display. Please come and visit at the important educational event.
MPSC is proud to return to the NEO Conference put on by Pediatrix at the Bonnet Creek Hilton in Orlando, Florida. MPSC will be displaying the HeRO duet and will be available to discuss the entire range of HeRO products. This conference will be held February 19-21, 2015.
MPSC is proud to sponsor the Neonatal Ventilation Workshop presented in association with The Kingdom of Bahrain Ministry of Health and Arabian Gulf University. This workshop will be held February 5th-8th, 2015 at the Arabian Gulf University.
MPSC is proud to join our local representatives, Infamed, at the Advances in Neonatal-Perinatal Medicine CME course in Philadelphia, Pennsylvania. This educational meeting is being hosted by the highly regarded Children's Hospital of Philadelphia. MPSC will be demonstrating the standalone HeRO duet monitor. Please come and speak with us.
MPSC was proud to exhibit the HeRO duet monitor at the Florida Association of Neonatal Nurse Practitioner's Conference held at the Sheraton Sand Key Resort October 14-18 in Clearwater Beach, Florida. We were delighted to join our local representatives, Bimeco Group, to demonstrate the HeRO System at this educational conference.
Dr. Karen Fairchild* from the University of Virginia will be presenting "Heart Rate and Cardiorespiratory Analysis for Early Detection of NEC" at the 2nd International Conference on NEC: SIGNEC UK held on Sept 3rd & 4th, 2014 in London. *Dr. Fairchild is not a paid representative of MPSC nor has any other conflict of interest with HeRO or MPSC, the producer of HeRO.
Medical Predictive Science Corporation has broadened its portfolio of life-saving neonatal monitors with HeRO Solo – a turnkey single patient HeRO monitor. HeRO monitors detect early signs of distress in NICU patients, commonly caused by infection and other potentially life-threatening illnesses. In the largest randomized controlled trial ever published among NICU patients, HeRO monitoring reduced mortality by 22%. Charlottesville, Va. (PRWEB), May 28, 2014 – Medical Predictive Science Corporation announced the immediate release for sale of HeRO Solo, the latest product in the life-saving line of HeRO NICU patient monitoring devices. “Standing alongside HeRO Symphony, HeRO ES, and HeRO Duet, we now fill out our product portfolio with HeRO Solo,” remarked CEO Will King. He added, “HeRO Solo provides our customers the same life-saving algorithm present in all HeRO products, now in a form factor that simplifies installation and clinical usage to the maximum possible extent.” HeRO is a pioneering monitoring system for premature infants that detects early signs of distress, commonly caused by infection and other potentially life-threatening illnesses. HeRO generates an hourly numeric score that quantifies the prevalence of abnormal patterns in each patient’s heart rate and provides a new tool for clinical assessment so that standard diagnostic and therapeutic decisions are better founded. HeRO monitoring was extensively tested in the largest randomized controlled trial of neonatal patients ever published. In that landmark study, mortality was reduced by 22% percent among those premature infants that received HeRO monitoring, compared with those that did not. “HeRO Solo will reach a new clinical audience. We expect widespread adoption both outside the US where networking infrastructure in the NICU is less prevalent, as well as inside the US where the move to single bed rooms necessitates [...]
17 March 2014 - ITV news speaks with Dr. Banerjee about HeRO from Singleton Hospital in Wales. http://www.itv.com/news/wales/story/2014-03-17/new-technology-could-save-premature-babies-lives/.
MPSC is pleased to welcome Singleton Hospital in Wales to the growing family of HeRO users. We are very proud to work with our partner, SLE Ltd, which represents MPSC in the United Kingdom. SLE helped the customer to successfully receive an innovation grant to deploy the HeRO System in their NICU.
A trio of new publications regarding HeRO hits the press. HeRO Publications lists the HeRO bibliography.
Further evidence of the effectiveness of HeRO is published in the Journal of Clinical Monitoring: Complex signals bioinformatics: evaluation of heart rate characteristics monitoring as a novel risk marker for neonatal sepsis.
Pallets of HeRO duets awaiting international pickup.
HeRO is now Multi-lingual! In response to the increasing demand for HeRO outside of the US, HeRO is now available supporting French, Italian, Russian, and Turkish. Look for more languages to be supported soon!
MPSC announces that Dr. Stefan Maxwell, a long-time neonatologist user of HeRO, has published an article in Neonatology Today telling his experiences with HeRO. Neonatology Today HeRO article
The HeRO System in use at Timpanogos Regional Medical Center in Orem, Utah.
MPSC announces that Canada Patent No. 2476607 has been issued further extending the intellectual property protection of the HeRO algorithms.
MPSC announces that our Italian distributor, Euromed Italy, has placed an order for HeRO duet. We are proud of this collaboration to introduce HeRO into the Italian Market.
MPSC is proud to announce the newest member of the HeRO family - HeRO duet. HeRO duet responds to the requests from our customers for a bedside version of the HeRO System. Using a touchscreen monitor for the interface, HeRO duet is simple to use and install. It was designed to be self-installed at the hospital. Each HeRO duet monitor connects to up to 2 physiological monitors. It supports data collection from the majority of physiological monitors.
MPSC receives the first order for HeRO duet to be delivered to customers in Turkey.
MPSC is proud to announce that the first installation of HeRO in the United Kingdom has been completed.
CHARLOTTESVILLE, Va., December 3, 2012 Medical Predictive Science Corporation (MPSC) announces that it has received a Medical Device License from Health Canada for the Heart Rate Observation System, or HeRO® System. This license allows the device to be marketed and sold in Canada indicated for the prediction of sepsis and improvement in mortality. MPSC CEO Will King commented, “MPSC is very proud to continue building upon the international acceptance of the HeRO System as a safe and effective medical device for infants in the neonatal intensive care units. Adding to the recently received CE marking, HeRO may now be marketed in the European Union, Canada, and the United States.” “MPSC looks to continue upon our recent successes with regulatory submissions in additional countries. HeRO is a quality product supported by the evidence from a large clinical trial which clearly demonstrated safety and effectiveness.” noted Ray Schumin, Director of Regulatory Affairs. “We are very pleased for the receipt of this license from Health Canada,” he added. "MPSC is immediately looking to engage partners or distributors in Canada that want to introduce this life-saving technology into Canadian NICUs. We look to fulfill the requests of potential customers in Canada who have expressed significant interest in the HeRO System and had been eagerly awaiting the availability of HeRO,” remarked Geoff Alms, PhD, Exec. VP of Sales and Marketing. HeRO is a pioneering monitoring system for premature infants that detects early signs of distress, commonly caused by infection and other potentially life-threatening illnesses. HeRO generates an hourly numeric score that quantifies the prevalence of abnormal patterns in each patient's heart rate and provides a new tool for clinical assessment so that standard diagnostic and therapeutic [...]
Cook Children's Medical Center in Fort Worth, TX, produced a video about their usage of HeRO.
CHARLOTTESVILLE, Va., November 8, 2012 Medical Predictive Science Corporation (MPSC) announces that it has received the CE mark for the Heart Rate Observation System, or HeRO® System. The CE mark allows the device to be marketed and sold in the European Union indicated for the prediction of sepsis and improvement in mortality. MPSC CEO Will King commented, “This is an important milestone in the adoption of the HeRO technology. Through this one action, we have effectively doubled the market for HeRO monitors.” “The evidence from the 3000-infant randomized controlled trial was clear and convincing: the HeRO System predicts sepsis and saves lives,” noted Ray Schumin, Director of Regulatory Affairs. “We couldn’t be more pleased with this outcome,” he added.  : MPSC is immediately looking to engage distributors in the European market at the MEDICA conference, in Dusseldorf, Germany later this month. “This is a great opportunity for us to build immediate momentum. Our distributor in the UK has already identified our first potential customer. I’m hopeful we can identify equally motivated sales partners throughout continental Europe,” remarked Geoff Alms, PhD, Exec. VP of Sales and Marketing. HeRO is a pioneering monitoring system for premature infants that detects early signs of distress, commonly caused by infection and other potentially life-threatening illnesses. HeRO generates an hourly numeric score that quantifies the prevalence of abnormal patterns in each patient's heart rate and provides a new tool for clinical assessment so that standard diagnostic and therapeutic decisions are better founded. : About MPSC MPSC is an entrepreneurial medical device company that translates ICU research discoveries to the patient’s bedside. The company develops predictive technology that detects imminent, catastrophic illness. MPSC’s HeRO monitor is the first of a [...]
CHARLOTTESVILLE, Va., Aug. 25, 2011 In a long-running randomized study of over 3,000 preterm infants, those whose care included the Heart Rate Observation System, or HeRO® monitor, experienced greater than 20 percent reduced mortality, effectively saving one infant’s life for every 48 who were monitored. The results of this multicenter study of the HeRO monitor, co-sponsored by the National Institutes of Health and Medical Predictive Science Corporation (MPSC), appear in The Journal of Pediatrics. HeRO is a pioneering monitoring system for premature infants that detects early signs of distress, commonly caused by infection and other potentially life-threatening illnesses. HeRO generates an hourly numeric score that quantifies the prevalence of abnormal patterns in each patient's heart rate and provides a new tool for clinical assessment so that standard diagnostic and therapeutic decisions are better founded. The study, “Mortality reduction by heart rate characteristic monitoring in very low birth weight neonates: a randomized trial,” was conducted from April 2004 to September 2010 at leading neonatal intensive care units (NICU) at the University of Virginia, Wake Forest University, University of Alabama at Birmingham, Vanderbilt University, University of Miami/Jackson Memorial Hospital, Greenville SC Hospital System, Winnie Palmer Children’s Hospital and Pennsylvania State University. There were 152 deaths (10.2 percent) in the group that received standard NICU care and 122 deaths (8.1 percent) in the group that received standard NICU care plus HeRO monitoring, an absolute risk reduction of 2.1 percent. There were no significant differences in demographics between the two groups, nor any of the other outcomes measured by the study. The study’s lead investigator and co-inventor J. Randall Moorman, M.D., a University of Virginia cardiologist said, “The HeRO monitor is the voice for infants who can’t speak for [...]
